Data Material
ALK Medical Affairs North America provides the resources found on this website for U.S. healthcare professionals only.
Safety profile of grass, ragweed, and house dust mite sublingual immunotherapy tablets in children and adolescents
Congress MaterialIntroduction
• Allergy immunotherapy (AIT) is the only disease-modifying treatment
for allergic rhinitis and/or conjunctivitis (AR/C)1
• In children, AIT has the added benefit of preventing the onset of
asthma symptoms and asthma medication use2-4
• The convenience of at-home administration and injection-free
administration may make sublingual immunotherapy (SLIT)-tablets
preferred by children (5-11 y), adolescents (12-17 y), and their
caregivers5
• The grass and ragweed SLIT-tablets are approved for ages 5+ years,
and the house dust mite (HDM) SLIT-tablet is approved for ages 12+
years for the treatment of AR/C
• A robust analysis of the safety of SLIT-tablets in children and
adolescents supports SLIT-tablets as a well tolerated alternative to
subcutaneous immunotherapy